#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial / Endpoints

Ayisha Sharma / endpoints - Bayer shared more details from its unexpected win in a Phase 3 study testing its next-generation blood thinner for secondary stroke prevention. The factor XIa inhibitor, named asundexian, reduced the occurrence of ischemic stroke by ...

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment


Saturday, February 7, 2026, 3:21 am / permalink 18873 / 2 stories in 4 wks



Related Stories




Related Tags



StackHealth Time Machine





NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.